TransMedics Group, Inc.
TMDX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $144 | $157 | $144 | $122 |
| % Growth | -8.6% | 9.6% | 18% | – |
| Cost of Goods Sold | $59 | $61 | $55 | $50 |
| Gross Profit | $85 | $97 | $88 | $72 |
| % Margin | 58.8% | 61.4% | 61.5% | 59.2% |
| R&D Expenses | $15 | $16 | $17 | $16 |
| G&A Expenses | $0 | $44 | $44 | $47 |
| SG&A Expenses | $46 | $44 | $44 | $47 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $61 | $60 | $61 | $63 |
| Operating Income | $23 | $37 | $27 | $9 |
| % Margin | 16.2% | 23.2% | 19.1% | 7.1% |
| Other Income/Exp. Net | -$0 | -$0 | -$1 | -$2 |
| Pre-Tax Income | $23 | $36 | $27 | $7 |
| Tax Expense | -$1 | $1 | $1 | $0 |
| Net Income | $24 | $35 | $26 | $7 |
| % Margin | 16.9% | 22.2% | 17.9% | 5.6% |
| EPS | 0.71 | 1.03 | 0.76 | 0.2 |
| % Growth | -31.1% | 35.5% | 280% | – |
| EPS Diluted | 0.66 | 0.92 | 0.7 | 0.19 |
| Weighted Avg Shares Out | 34 | 34 | 34 | 34 |
| Weighted Avg Shares Out Dil | 41 | 41 | 40 | 35 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $3 | $0 | $3 |
| Interest Expense | $3 | $3 | $3 | $4 |
| Depreciation & Amortization | $7 | $7 | $6 | $6 |
| EBITDA | $33 | $46 | $36 | $16 |
| % Margin | 23.2% | 29.5% | 25.3% | 13.4% |